Literature DB >> 229747

Comparative pathogenesis studies with oncogenic and nononcogenic Marek's disease viruses and turkey herpesvirus.

B W Calnek, J C Carlisle, J Fabricant, K K Murthy, K A Schat.   

Abstract

An apparently nononcogenic Marek's disease virus (SB-1) and turkey herpesvirus could be readily isolated from spleen, bursa of Fabricius, thymus, and peripheral blood lymphocytes of chickens beginning 4 to 6 days after inoculation, but unlike infections with two isolates of oncogenic Marek's disease virus (JM-10 and CU-2), virus replication in these cells was rare, and necrosis in the organs was essentially absent. Splenic enlargement was observed regularly during the first 4 to 11 days after inoculation, and Marek's disease tumor-associated surface antigen was observed on splenic and other lymphocytes in the four viral inoculation groups. Cellular cytotoxicity of splenic lymphocytes was demonstrated in vitro with cultured Marek's disease tumor cells (MSB-1 lymphoblastoid cell line) as the target in a chromium-release assay. The four viral infections induced sensitized lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 229747

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  16 in total

1.  Persistence of Marek's disease virus in a subpopulation of B cells that is transformed by avian leukosis virus, but not in normal bursal B cells.

Authors:  E Fynan; T M Block; J DuHadaway; W Olson; D L Ewert
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

2.  Marek's disease virus-encoded Meq gene is involved in transformation of lymphocytes but is dispensable for replication.

Authors:  Blanca Lupiani; Lucy F Lee; Xiaoping Cui; Isabel Gimeno; Amy Anderson; Robin W Morgan; Robert F Silva; Richard L Witter; Hsing-Jien Kung; Sanjay M Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

3.  Pathogenesis of Marek's disease; effect of immunization with inactivated viral and tumor-associated antigens.

Authors:  K K Murthy; B W Calnek
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

4.  Synthesis, processing, and secretion of the Marek's disease herpesvirus A antigen glycoprotein.

Authors:  R J Isfort; R A Stringer; H J Kung; L F Velicer
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

5.  Latent herpesvirus infection of testes and spinal ganglia of turkeys with semen abnormalities.

Authors:  D A Benfield; H K Adldinger
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

6.  Spontaneous and induced herpesvirus genome expression in Marek's disease tumor cell lines.

Authors:  B W Calnek; W R Shek; K A Schat
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

7.  Influence of the bursa of Fabricius on the pathogenesis of Marek's disease.

Authors:  K A Schat; B W Calnek; J Fabricant
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

8.  In vitro cytotoxicity against Marek's disease lymphoblastoid cell lines after enzymatic removal of Marek's disease tumor-associated surface antigen.

Authors:  K A Schat; K K Murthy
Journal:  J Virol       Date:  1980-04       Impact factor: 5.103

9.  Marek's disease virus-encoded vIL-8 gene is involved in early cytolytic infection but dispensable for establishment of latency.

Authors:  Xiaoping Cui; Lucy F Lee; Willie M Reed; Hsing-Jien Kung; Sanjay M Reddy
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Retroviral insertional activation in a herpesvirus: transcriptional activation of US genes by an integrated long terminal repeat in a Marek's disease virus clone.

Authors:  D Jones; P Brunovskis; R Witter; H J Kung
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.